On Wednesday, UK-based biopharmaceutical company Amryt Pharma, which develops innovative treatments for rare diseases, made its U.S. debut on the Nasdaq, trading as AMYT. 

This isn't the company's first foray into the stock market, but CEO Joe Wiley says the expansion to the U.S. should help the company grow its business further.

"We are already listed in London, so we are now dual-listed in both the U.S. and the UK," Wiley said. "We also hope to enhance our value of our equity on both sides of the Atlantic through this dual-listing. Thirdly, we believe this enhances our credibility as a biotech company and our access to deal globally as we continue our strategy to acquire, develop, and commercialize."

One other factor contributing to Amryt Pharma's decision to go public in U.S. markets was due to where the company's shareholders are located. Roughly 70 percent of the company's shareholders are already located in North America and the company hopes to expand its reach there.

"We believe that this IPO will increase the awareness of Amryt in the U.S. by increasing our Amyrt coverage." Wiley then added, "We believe that we can access a deeper pool of capital and healthcare investors in the U.S. This will ultimately drive liquidity in our shares, which is what our goal is."   

Although not in the race to develop a COVID-19 vaccine, by focusing on rare and orphan diseases, the company believes its future is bright. As an example, Wiley pointed to his company's study of epidermolysis bullosa, a group of rare and genetic disorders of the skin, as one reason investors should remain interested.

"Analysts who cover this area believe that north of a $1 billion market opportunity...We actually did the world's largest-ever study in EB...we will read our data from that in late Q3 or early Q4 this year."

Share:
More In Business
Starbucks’ Change Flushes Out a Debate Over Public Restroom Access
Starbucks’ decision to restrict its restrooms to paying customers has flushed out a wider problem: a patchwork of restroom use policies that varies by state and city. Starbucks announced last week a new code of conduct that says people need to make a purchase if they want to hang out or use the restroom. The coffee chain's policy change for bathroom privileges has left Americans confused and divided over who gets to go and when. The American Restroom Association, a public toilet advocacy group, was among the critics. Rules about restroom access in restaurants vary by state, city and county. The National Retail Federation says private businesses have a right to limit restroom use.
Trump Highlights Partnership Investing $500 Billion in AI
President Donald Trump is talking up a joint venture investing up to $500 billion for infrastructure tied to artificial intelligence by a new partnership formed by OpenAI, Oracle and SoftBank. The new entity, Stargate, will start building out data centers and the electricity generation needed for the further development of the fast-evolving AI in Texas, according to the White House. The initial investment is expected to be $100 billion and could reach five times that sum. While Trump has seized on similar announcements to show that his presidency is boosting the economy, there were already expectations of a massive buildout of data centers and electricity plants needed for the development of AI.
Load More